Kunkeaw, Nawapol http://orcid.org/0000-0003-2964-5446
Nguitragool, Wang http://orcid.org/0000-0002-5484-7130
Takashima, Eizo http://orcid.org/0000-0001-9070-8499
Kangwanrangsan, Niwat
Muramatsu, Hiromi http://orcid.org/0000-0003-1544-1493
Tachibana, Mayumi
Ishino, Tomoko
Lin, Paulo J. C.
Tam, Ying K. http://orcid.org/0000-0002-4083-5251
Pichyangkul, Sathit
Tsuboi, Takafumi http://orcid.org/0000-0002-7415-1325
Pardi, Norbert http://orcid.org/0000-0003-1008-6242
Sattabongkot, Jetsumon http://orcid.org/0000-0002-3938-4588
Article History
Received: 28 June 2023
Accepted: 9 October 2023
First Online: 14 December 2023
Change Date: 19 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41541-024-00837-9
Competing interests
: N.P. and Y.K.T. are named on a patent describing the use of nucleoside-modified mRNA in lipid nanoparticles as a vaccine platform. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from the licensing of our patents. Y.K.T. and P.J.C.L. are the employees of Acuitas Therapeutics, a company focused on the development of LNP nucleic acid delivery systems. J.S., N. Kunkeaw, N.P., S.P., and W.N. are named on a patent describing the development of Pvs25 mRNA–LNPs (PCT/TH2023/000006). N.P. served on the mRNA strategic advisory board of Sanofi Pasteur in 2022. N.P. is a member of the Scientific Advisory Board of AldexChem.